Achieve Life Sciences, Inc. (ACHV): Total Assets
$41.79M
As of 2025-12-31
$190.44M
As of 2026-06-30
+11.7%
3-year compound annual growth
+0.7%
5-year compound annual growth
-3.3%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $41.79M | +8.2% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $38.63M | +99.4% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $19.37M | -35.4% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $29.97M | -36.9% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $47.52M | +17.9% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $40.30M | +91.2% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $21.08M | +10.4% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $19.08M | +92.9% | 2020-03-13, Balance as of period end |
| 2017-12-31 | $9.89M | +159.8% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $3.81M | -93.5% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $58.21M | +3.4% | 2017-02-23, Balance as of period end |
| 2014-12-31 | $56.29M | +1.1% | 2016-03-09, Balance as of period end |
| 2013-12-31 | $55.69M | -32.1% | 2015-03-26, Balance as of period end |
| 2012-12-31 | $82.02M | +20.6% | 2014-03-11, Balance as of period end |
| 2011-12-31 | $68.02M | -24.4% | 2013-03-07, Balance as of period end |
| 2010-12-31 | $89.92M | n/a | 2012-03-08, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Achieve Life Sciences, Inc. (ACHV) | 2025-12-31 | $41.79M | +8.2% |
| Q/C Technologies, Inc. (QCLS) | 2025-12-31 | $41.17M | +92.2% |
| Immucell Corp (ICCC) | 2025-12-31 | $42.53M | -5.7% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $30.24M | +59.8% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $25.76M | -26.6% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $103.58M | -12.8% |
| Cardio Diagnostics Holdings, Inc. (CDIO) | 2025-12-31 | $7.77M | -26.8% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $6.90M | -26.6% |
| Biomerica Inc (BMRA) | 2026-05-31 | $6.76M | +13.7% |
Compare ACHV, QCLS, ICCC, NNNN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗